Adial Pharmaceuticals Inc (ADIL)
1.65
-0.06
(-3.51%)
USD |
NASDAQ |
Apr 25, 11:46
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.691M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -81.51% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.638 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.30% |
Profile
| Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. |
| URL | https://www.adialpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Virginia |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Apr. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. |
| URL | https://www.adialpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Virginia |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Apr. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |